Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Collegium Pharmaceutical Stock Down 1.1 %
Collegium Pharmaceutical stock opened at $37.19 on Friday. Collegium Pharmaceutical, Inc. has a twelve month low of $20.95 and a twelve month high of $40.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. The firm has a market cap of $1.22 billion, a PE ratio of 15.50 and a beta of 0.94. The firm’s 50 day moving average price is $34.91 and its two-hundred day moving average price is $35.30.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. Collegium Pharmaceutical’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.13 earnings per share. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.89 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Collegium Pharmaceutical
Institutional Investors Weigh In On Collegium Pharmaceutical
Hedge funds and other institutional investors have recently made changes to their positions in the company. Gladius Capital Management LP bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at approximately $32,000. Principal Securities Inc. bought a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $40,000. nVerses Capital LLC lifted its stake in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares during the last quarter. Assetmark Inc. grew its position in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth $204,000.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Stories
- Five stocks we like better than Collegium Pharmaceutical
- How to Invest in Biotech Stocks
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- How to buy stock: A step-by-step guide for beginners
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- How to Invest in the FAANG Stocks
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.